Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhixue Quyu Mingmu is a Traditional Chinese Medicine (TCM) formula developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is primarily indicated for the treatment of retinal vein occlusion (RVO), specifically for patients diagnosed with the "blood stasis and Yin deficiency" syndrome. The formula's name reflects its therapeutic actions: "Zhixue" (hemostasis), "Quyu" (resolving blood stasis), and "Mingmu" (improving eyesight). It is formulated as an oral tablet and has been evaluated in multicenter, randomized, double-blind clinical trials to assess its efficacy in reducing retinal hemorrhage and improving visual acuity compared to other TCM treatments like Compound Xue-shuan-tong capsules. Its mechanism involves improving retinal microcirculation and facilitating the absorption of retinal hemorrhages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhixue quyu mingmu.